Eurofins acquires Hygel
Founded in 1902, Hygel has developed into one of the largest clinical diagnostics providers in North Rhine-Westphalia, the most populous federal state in Germany, with access to over 900 physicians, 120 hospitals and around 20 local health authorities. As a reference clinical laboratory, Hygel serves more than 50% of the healthcare industry in the Northern Ruhr area and Iserlohn region, with multiple accreditations from both private and public health authorities and agencies. The company employs 370 staff across its 3 main sites as well as in laboratories that it operates for 4 local hospitals, and generated revenues in excess of EUR 35m in 2016.
The acquisition of Hygel provides Eurofins entry into the clinical diagnostic testing market in Germany, and reinforces the Group’s footprint to serve healthcare professionals in Europe. In return, Eurofins’ vast analytical portfolio and technical resources, as well as the Group’s world class laboratory and systems infrastructure, should support the further development of Hygel’s portfolio of diagnostic tests and services, as well as the expansion of its footprint and client reach in the rest of the country.
Comment from Dr. Astrid Dirkes-Kersting, Managing Director, Hygel: “We are excited to be joining the Eurofins family of laboratories and look forward to the next phase of our development within the Group. We are confident that with access to Eurofins’ network and technical competencies, we should be able to expand our analytical portfolio and services to benefit all our existing and future clients.”
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Hygel expands Eurofins’ clinical diagnostic footprint in Europe, and reinforces the platform on which to deploy the Group’s technical know-how and proprietary technologies, including our competencies in specialty diagnostic testing. We are committed to supporting Hygel in further developing its service offering and its geographic footprint to better serve the healthcare industry in Germany.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.